(MENAFN- PR Newswire) DUBLIN, March 7, 2024 /PRNewswire/ -- The
"Global Dilated Cardiomyopathy Market by Drug Class Inhibitors, Treatment Type, Route of Administration, Distribution Channel, and By Region" report has been added to
ResearchAndMarkets's offering.
The global dilated cardiomyopathy (DCM) market size was estimated to be USD 422.6 million in 2023 and is expected to reach USD 652.0 million by 2034 with a CAGR of 4.02% during the forecast period 2024-2034. The rising prevalence of heart failure, growing awareness of DCM, rising government initiatives, development of novel therapies, technological advancements, and collaborations and partnerships will drive the market growth.
Heart failure is mostly caused by DCM, which accounts for 30-40% of cases worldwide. Numerous reasons, such as aging populations, unhealthy lifestyles, and the increased burden of chronic illnesses like diabetes and obesity, are to blame for the rising prevalence of heart failure. For instance, Novartis AG presented promising Phase 3 results in December 2023 on the reduction of hospitalizations for heart failure among patients with preserved ejection fraction (HFpEF) and DCM. The medication Entresto (sacubitril/valsartan).
By drug class, the angiotensin-converting enzyme (ACE) inhibitors segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the widespread adoption of ACE inhibitors as a primary therapeutic intervention for Dilated Cardiomyopathy. This class of medications, including widely prescribed drugs like enalapril, lisinopril, and ramipril, demonstrated efficacy in managing the condition by inhibiting the angiotensin-converting enzyme, thereby reducing the production of angiotensin II. Additionally, the angiotensin II receptor blockers segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of their efficacy and tolerability in the management of Dilated Cardiomyopathy, coupled with a rising preference for alternative therapeutic options.
By treatment type, the medication segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the increased demand for a diverse range of pharmaceutical interventions, including beta-blockers, diuretics, anticoagulants, and other medications, for the comprehensive management of Dilated Cardiomyopathy. Additionally, the implantable devices segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased adoption of advanced and innovative technologies for the management of Dilated Cardiomyopathy, with implantable devices offering significant therapeutic benefits.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the convenience and widespread patient acceptance of oral medications, particularly in the form of tablets and capsules, for the management of Dilated Cardiomyopathy. Additionally, the parenteral segment is predicted to grow at the fastest CAGR during the forecast period owing to the increased focus on rapid and targeted drug delivery, especially in acute and critical situations associated with Dilated Cardiomyopathy, where parenteral administration offers quicker onset of action and precise dosage control.
By distribution channel, the hospital pharmacy segment accounted for the highest revenue-grossing segment in the global dilated cardiomyopathy market in 2023 owing to the central role of hospitals in the diagnosis, treatment, and management of Dilated Cardiomyopathy, with hospital pharmacies serving as key distribution points for a wide range of medications and therapeutic interventions. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend of digital healthcare adoption, improved accessibility, and the convenience offered by online pharmacies in catering to the evolving needs of patients seeking Dilated Cardiomyopathy medications.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
Base Year: 2023 Forecast Period: 2024-2034 Study Coverage Market Forecast by Drug Class, Treatment Type, Route of Administration, and Distribution Channel Market Forecast for 5 Regions and 17+ Countries North America (U.S. and Canada) Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe) Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC) Latin America (Brazil, Mexico, Argentina, Rest of LATAM) MEA (South Africa, GCC, Rest of MEA)
Company Profiles of the Top 10+ Major Market Players
Key Topics Covered:
1. Research Methodology
2. Introduction
3. Executive Summary
4. Market Environment Analysis
4.1. Porter's 5 Forces Analysis
4.2. PESTEL Analysis
4.3. SWOT Analysis
5. Market Dynamics
6. COVID-19 Impact Analysis
7. Dilated Cardiomyopathy Market: Drug Class Estimates & Trend Analysis
7.1. Drug Class Segment Opportunity Analysis
7.2. Angiotensin-converting enzyme (ACE) Inhibitors
7.3. Beta-blockers
7.4. Aldosterone antagonists
7.5. Angiotensin II Receptor Blockers
8. Dilated Cardiomyopathy Market: Treatment Type Estimates & Trend Analysis
8.1. Treatment Type Segment Opportunity Analysis
8.2. Medication
8.3. Implantable Devices
8.4. Heart Pumps
8.5. Cardioverter-Defibrillators
9. Dilated Cardiomyopathy Market: Route of Administration Estimates & Trend Analysis
9.1. Route of Administration Segment Opportunity Analysis
9.2. Oral
9.3. Parenteral
10. Dilated Cardiomyopathy Market: Distribution Channel Estimates & Trend Analysis
10.1. Distribution Channel Segment Opportunity Analysis
10.2. Hospital Pharmacy
10.3. Retail Pharmacy
10.4. Online Pharmacies
11. Regional Market Analysis
11.1. Regional Market Opportunity Analysis
12. North America Dilated Cardiomyopathy Market
13. Europe Global Dilated Cardiomyopathy Market
14. Asia Pacific Global Dilated Cardiomyopathy Market
15. Latin America Global Dilated Cardiomyopathy Market
16. MEA Global Dilated Cardiomyopathy Market
17. Competitor Analysis
17.1. Company Market Share Analysis, 2023
17.2. Major Recent Developments
18. Company Profiles
Novartis Pfizer Bristol Myers Squibb Merck Johnson & Johnson AstraZeneca PLC Amgen Inc. Bayer AG Sanofi S.A. Eli Lilly and Company Abbott Laboratories Boehringer Ingelheim International GlaxoSmithKline Mylan Roche Holding
For more information about this report visit
About ResearchAndMarkets
ResearchAndMarkets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo:
SOURCE Research and Markets
MENAFN07032024003732001241ID1107950777
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.